^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) + Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
215 | Sintilimab plus Chidamide for Relapsed/Refractory (r/r) Extranodal NK/T Cell Lymphoma (ENKTL): A Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)
Published date:
06/09/2021
Excerpt:
Of 37 response evaluable patients, 22 patients (59.5%) achieved an ORR including 18 (48.6%) patients with CR...We assessed PD-L1 (22C3) expression by combined positivity score (CPS). The median CPS was 40.0, patients with CPS ≥ 30 exhibited benefit...Sintilimab combined with Chidamide showed manageable safety profile and yielded effective antitumor activity, durable response in patients with r/r ENKTL for the first time.
Trial ID:
